Clinical trial · Interventional
Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
Phase Ib Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is an open, single-center, multi-cohort phase Ib exploratory study, and 50 subjects are planned to be enrolled to observe the objective response rate of each subject. The safety evaluation of this study adopts common terminology criteria for adverse events version (CTCAE) 5.0 to evaluate the adverse events of drugs. Efficacy was evaluated using response evaluation criteria in solid tumors version (RECIST) 1.1 for immune-based therapeutics criteria.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Toripalimab injection | Drug | Toripalimab | ALIAS |
| TQB2618 injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- TQB2618 injection combined with Toripalimab injection
- description
- TQB2618 injection combined with Toripalimab injection，21 days as a treatment cycle.
- interventionNames
- Drug: TQB2618 injection
- Drug: Toripalimab injection
Primary outcomes (3)
- measure
- Dose-limiting toxicity
- timeFrame
- Initial administration up to 21 days
- description
- Certain adverse events related to the test drug occurred within 1 treatment cycle (21 days) of the subjects' first dose
- measure
- phase II recommended dose
- timeFrame
- At the end of phase I, 1 subject received the first dose up to 21 days
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 1 Age: 18-75 years old;ECOG PS score: 0\~1;The expected survival is over 3 months * 2 Patients with advanced melanoma diagnosed histologically and/or cytologically * 3 At least one measurable lesion was confirmed according to RECIST 1.1 criteria * 4 Major organs are functioning normally * 5 Female subjects of reproductive age should agree to use contraceptive methods (such as intrauterine devices, birth control pills, or condoms) during the study period and for 6 months after the end of the study;Negative serum pregnancy/urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects;Male subjects should agree to use contraception during the study and for six months after the end of the study period Exclusion Criteria: * 1 Present or present with other malignant tumors within 3 years prior to first use * 2 Unalleviated toxicity above CTCAE grade 1 due to any prior treatment * 3 Major surgical treatment and significant traumatic injury were performed within 28 days prior to initial administration * 4 A wound or fracture that has not healed for a long time * 5 Those who have a history of psychotropic drug abuse and can't get rid of it or have mental disorders * 6 Subject with any severe and/or uncontrolled disease * 7 Prior chemotherapy within 3 weeks prior to initial drug use, and prior radiotherapy or other antineoplastic drugs within 2 weeks prior to initial drug use * 8 Those who have participated in and used other antitumor clinical trials within 4 weeks prior to the first drug use
References
Publications (0)
Data not yet available